Angiex, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.angiex.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- CancerAdvanced CancerLocally Advanced CarcinomaMetastatic Solid TumorBreast CancerProstate CancerColorectal CancerPancreatic CancerLiver CancerAngiosarcoma
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Angiex, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06440005
- Locations
- 🇺🇸
Sarah Cannon Research Center, Nashville, Tennessee, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
News
No news found